Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAreyl Goff

Discussion

Loading...

Member takes

Overview

Phase II trial shows 55% IMWG response improvement in multiple myeloma patients with persistent MRD after ASCT, suggesting potential for CAR T-cell therapy.

Key Points

  • To assess the efficacy of lenalidomide and isatuximab maintenance on MRD negativity following ASCT in multiple myeloma patients.
  • Phase II clinical trial assessing MRD after autologous stem cell transplant
  • Patients received lenalidomide and isatuximab maintenance therapy
  • Primary endpoint: MRD negativity as measured by next-generation sequencing assay
  • Only 7% of patients achieved MRD negativity after treatment
  • 55% showed improvement in IMWG response at 6 months
  • 12-month progression-free survival rate was 83%

Cite This Study

Areyl Goff (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e013https://doi.org/10.1182/blood-2025-5758
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MRD-guided induction-intensification with daratumumab–carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma2026
  2. 2Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network ( EMN ) Italy2026
  3. 3Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance2025 · 3 citations
  4. 4Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese2025
  5. 5Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group2024 · 5 citations